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Abstract
Our recent studies have uncovered that aggregation-prone proinsulin preserves a low relative folding rate and maintains a
homeostatic balance of natively and non-natively folded states (i.e., proinsulin homeostasis, PIHO) in b-cells as a result of the
integration of maturation and disposal processes. Control of precursor maturation and disposal is thus an early regulative
mechanism in the insulin production of b-cells. Herein, we show pathways involved in the disposal of endogenous
proinsulin at the early secretory pathway. We conducted metabolic-labeling, immunoblotting, and immunohistochemistry
studies to examine the effects of selective proteasome and lysosome or autophagy inhibitors on the kinetics of proinsulin
and control proteins in various post-translational courses. Our metabolic-labeling studies found that the main lysosomal and
ancillary proteasomal pathways participate in the heavy clearance of insulin precursor in mouse islets/b-cells cultured at the
mimic physiological glucose concentrations. Further immunoblotting and immunohistochemistry studies in cloned b-cells
validated that among secretory proteins, insulin precursor is heavily and preferentially removed. The rapid disposal of a
large amount of insulin precursor after translation is achieved mainly through lysosomal autophagy and the subsequent
basal disposals are carried out by both lysosomal and proteasomal pathways within a 30 to 60-minute post-translational
process. The findings provide the first clear demonstration that lysosomal and proteasomal pathways both play roles in the
normal maintenance of PIHO for insulin production, and defined the physiological participation of lysosomal autophagy in
the protein quality control at the early secretory pathway of pancreatic b-cells.
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Introduction
Polypeptide homeostasis in normal cells (PHIC) is a dynamic
equilibrium maintained by integral processes, such as the synthesis,
folding, clearance, and transport of proteins to functional
destinations [1]. Perturbations of PHIC can result in various
diseases, includingearly-onsetdiabetes in the Ins2
+/Akita miceand up
to20%ofneonataldiabetesinhumans [2–4],whichresultprimarily
from proinsulin homeostasis disorders induced by varied mutations
in the preproinsulin molecule [1]. In eukaryotic cells, the lysosomal
and proteasomal pathways are the two main routes responsible for
protein disposal in the normal maintenance of PHIC. Proteasomes
mainly clean misfolded proteins marked by (poly)ubiquitination
[5,6], and lysosomes digest cytosolic cargo through macroauto-
phagy, microautophagy, and chaperone-mediated autophagy
(CMA) pathways [7,8]. Multiple clearance mechanisms are
implicated in the homeostasis of individual proteins in cells. For
example, the macroautophagy, CMA, and proteasomal pathways
all participate in clearance of wild-type a-synuclein, a cytosolic
protein associated with Parkinson disease [9,10].
It is recognized that in eukaryotic cells about one-fifth to one-
third of nascent proteins are targeted to the endoplasmic reticulum
(ER) wherein structural maturation and modifications of secretory
protein take place for transit to the intracompartmental lumen and
membrane, and ultimate secretion [5,6]. Normally, a set of
molecular helpers, such as various chaperones and adaptors, assist
maturation. Recent findings reveal that under stress, adaptive
mechanisms function to protect the ER (see reviews: 5,6,11,12),
including the (a) translational attenuation and enhanced tran-
scription of selected chaperone genes, (b) retro-translocation of
misfolded proteins for ER-associated degradation (ERAD) by the
proteasome, (c) ER-phagy (ER consumption by autophagy)
[8,13,14], and (d) substrate-specific translocational attenuation
[15] and proteasomal degradation of the proteins rejected by the
ER translocon [16].
Under most physiological conditions, proteasomes can rapidly
degrade approximately 30% of nascent proteins [17], which may
include a fraction of proteins destined naturally for the secretory
pathway. However, it remains unclear whether the proteasomal
pathway alone or in combination with the lysosomal pathway
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secretory proteins at the early secretory pathway. Although
adaptive responses, such as ER-phagy, have been elucidated
under stress conditions, the physiological significance of the
lysosomal pathway in the early secretory pathway remains to be
defined.
Pancreatic b-cells (hereafter termed ‘‘b-cells’’) are equipped with
a well developed secretory pathway for the production of insulin.
Proinsulin is the most abundant insulin precursor made in the
pancreatic b-cells [18]. Higher glucose stimulation can increase
proinsulin synthesis 50 times at the translational level [19].
Proinsulin will be processed into insulin in a general 2-hour course
[18] that involves an early complex process of folding/maturation
mainly in the ER and Golgi compartments. After a general 40–
60 min trip through the ER and Golgi, proinsulin moves into the
trans Golgi compartment and/or immature granules wherein C-
peptide is removed. As a result, proinsulin is converted to insulin
and stored in mature granules ready for release [18]. Our recent
studies have uncovered that proinsulin inherent with an
aggregation-prone nature preserves a low relative folding rate
compared to control secretory proteins [1]. Proinsulin thus
maintains a homeostatic balance of natively and non-natively
folded states (i.e., proinsulin homeostasis, PIHO) at the early
secretory pathways of b-cells as a result of the integration of
maturation and clearance processes [1]. However, it remains
unclear whether the two main protein disposal pathways
participate in the normal control of insulin precursor disposal in
pancreatic b-cells.
In this study, we have taken advantage of the recently improved
metabolic-labeling and C-peptide immunoblotting approaches [1]
combined with immunohistochemistry studies and characterized
the roles of proteasomes and lysosomes in the early post-
translational processing of insulin precursor. Mouse islets/b-cells
during 24-hour pre-experimental and various experimental
periods were incubated in routinely applied culture media
containing mimic physiological glucose concentrations (5.5 mM,
cloned b-cells; 11 mM, islets). By examining the changes in levels/
states of (un)labeled proinsulin and control proteins in various
post-translational courses with selective proteasomal and/or
autophagy lysosomal inhibition, we found that the lysosomal and
proteasomal pathways both function in disposals of insulin
precursor for the normal maintenance of PIHO during insulin
production. We also define a physiological role of lysosomal
autophagy in the customary quality control at the early secretory
pathway of pancreatic b-cells for the first time.
Results
Lysosomal or proteasomal inhibition preserves
35S-
labeled proinsulin
During a 15-minute chase, we compared the effect of lactacystin
(10 mM) or chloroquine (100 mg/mL) with that of controls, e.g.,
antimycin (10 mM) or brefeldin A (10 mg/mL), on the kinetics of
proinsulin labeled with
35S-methionine (Met) for 5 minutes in
MIN6 b-cells. Met residue occurs only in proinsulin 2 in rodents,
not in proinsulin 1. In this 15-minute chase, just as we previously
observed [1], addition of the ATP production inhibitor antimycin
largely blocked a heavy clearance of proinsulin, and a plateau of
35S-proinsulin appeared (refer to the monomers on the reduced
gel). The proinsulin level at the natural 3-minute chase was about
51% of the plateau and at the 15-minute chase, about 39%
(Figure 1A, B; Table S1; P,0.01; n=3). Results consistently
indicate that 49% (51% from 100%, at 3 minutes) and 12% (39%
from 51%%, at 15 minutes) of
35S-proinsulin molecules were
removed by rapid disposal, a process occurring immediately
following translation [1], and a subsequent basal clearance during
the time frame required for proinsulin maturation and departure
from the ER as demonstrated previously [18,20]. Compared to the
39% proinsulin level after the 15-minute natural chase, 47% was
preserved with the addition of chloroquine, an agent for
autophagy measurements that inhibits lysosomal acidification
[21,22], and 9% was preserved with addition of lactacystin, a
specific proteasomal inhibitor (P,0.01; n=3). In addition, no
proinsulin was detected in the immunoprecipitates of control sera/
immunoglobulin (Figure S1), further supporting that proinsulin
preserved by selective lysosomal or proteasomal inhibition and
evident in the immunoprecipitates of insulin and C-peptide
antisera is specifically detected and mainly destined for natural
clearance.
Interestingly, a significant fraction of proinsulin was also
preserved by adding brefeldin A, an agent targeting guanosine-
59-triphosphate exchange factors and interfering with the
formation and conveyance of protein transport vesicles
(Figure 1A, B). The molecular targets of brefeldin A appear
(in)directly involved in the process of proinsulin disposal in
addition to its known role in cellular protein traffic. Block of the
routine path from the ER to the Golgi transport alone cannot fully
explain the entire preservation of proinsulin by brefeldin A. An
enlarged subcompartment of the ER after addition of brefeldin A,
the ‘‘brefeldin A body’’ defined in islet b-cells [23], may be linked
to proinsulin removal somehow. Comparison of proinsulin states
between non-reduced and reduced gels (Figure 1B) showed that
the proinsulin preserved by the applied agents was concentrated
mainly in the non-monomer states, which are primarily formed in
vivo [1].
Addition of lactacystin or chloroquine during a 15-minute chase
after a 10-minute pulse resulted in an increase of about 11 or 28%
in the level of
35S-proinsulin in cultured mouse islets (Figure 1C,
D; control versus lactacystin, 100.0 6 3.3 versus 111.3 6 5.1%,
P,0.05; control versus chloroquine, 100.0 6 3.3 versus 128.1 6
7.2%, P,0.01; n=3), indicating the likely involvement of the
lysosomal and proteasomal pathways in removal of nascent
proinsulin in islets and cloned b-cells. A potent difference in the
effects of chloroquine between MIN6 b-cells and islets is most
likely due to possible diversities in the machinery of clearance and
maturation. As observed previously [1], in insulin and C-peptide
immunoprecipitates (Figure 1B, D), unidentified molecular helpers
are more abundant in MIN6 b-cells than in islets (irrespective of a
possibly non-specific immunoglobulin-binding fraction, and they
appear in the upper area of the reduced gel. See Figure S1). The
helpers are components of proinsulin non-monomer states, which
appear in the upper area of the non-reduced gel, and could
function in proinsulin disposal, maturation, and even transport [1].
The difference may also have been affected by the glucose
concentrations (5.5 mM, cloned b-cells; 11 mM, islets) we applied
during the one day pre-experimental, 30 minutes Met starvation,
and experimental period to mimic normal mice glycemic levels as
used generally in the in vitro culture of islets/b-cells.
Validation of the roles of lysosomes and proteasomes in
proinsulin removal
To confirm the roles of lysosomes and proteasomes, we used C-
peptide immunoblot and assessed the level changes of newly
synthesized proinsulin during a 2-hour post-translational process
in which Ins2
+/+ b-cells [24] were exposed to cycloheximide (Chx;
100 mg/mL, a protein synthesis inhibitor) with/without lysosomal
or proteasomal inhibitors. Like the MIN6 b-cells, the Ins2
+/+ b-
cells preserve the basic characteristics of natural pancreatic b-cell
Lysosomal-Proteasomal Favored Proinsulin Disposal
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response to glucose (unpublished data), proinsulin states [1], and
ER stress responses [24]. A 2-hour course generally covers a
complete post-translational process from the appearance of
nascent proinsulin to the release of insulin [18].
Compared to the proinsulin level (normalized by b-tubulin if
not specifically stated) in the untreated control, an average of 19%
of proinsulin that was synthesized prior to the addition of the Chx
was retained by adding Chx alone and 45.3%, by adding Chx and
chloroquine (50–400 mg/mL, described as the Chx/chloroquine
below for combined agents). Addition of trans-epoxysuccinyl-L-
leucylamido-(4-guanidino)butane (E-64; 25–100 mM), a cysteine
protease (e.g., cathepsins) inhibitor, caused retention of 27.8% of
proinsulin versus 13.1% retained in the treatment with Chx alone
(Figure 2, left panel; Chx versus Chx/Chlotoquine, 19.0 6 5.1
versus 45.3 6 8.2%, P,0.01; Chx versus Chx/E-64, 13.1 6 5.3
versus 27.8 6 6.1%, P,0.05; n=4). The lower potency of E-64
than that of chloroquine may be partially attributable to the
relatively limited targets of E64 versus the entire lysosomal lumen
targeted by chloroquine. Compared to adding only Chx, addition
of proteasomal inhibitor N-benzyloxycarbonyl-leucyl-leucyl-leuc-
inal (MG-132; 10–20 mM) preserved 6% of proinsulin or addition
of lactacystin (5–20 mM) preserved 16.4% (Figure 2, right panel;
Chx versus Chx/MG-132, 17.1 6 2.5 versus 23.1 6 2.8%,
P,0.05; Chx versus Chx/lactacystin, 31.0 6 4.9 versus 47.4 6
6.2%, P,0.05; n= 4). No significantly dose-dependent effect of
individual inhibitors was observed despite a somewhat relevance
between dose and effect appeared only in lower ranges of the
lysosomal inhibitors. Both metabolic-labeling and immunoblotting
analyses (Figures 1, 2) strongly suggest the participation of
proteasomal and lysosomal pathways in endogenous proinsulin
clearance in b-cells.
Figure 1. Lysosomal or proteasomal inhibition preserves
35S-methionine (Met) labeled nascent proinsulin in mouse islets/b-cells.
After 24-hour pre-experimental culture with the 5.5 mM (MIN6 b-cells) or 11 mM (islets) glucose concentration, MIN6 b-cells (A and B) or islets (C)
were chased for the indicated times with/without chloroquine (100 mg/mL), lactacystin (10 mM), antimycin (10 mM), or brefeldin A (10 mg/mL) after a
pulse for the indicated times with
35S-Met. Cellular proteins were then subjected to immunoprecipitation with insulin and C-peptide antisera. Equal
amounts of individual immunoprecipitates were resolved by 10% tricine non-reduced and/or reduced SDS-PAGE for radiography. Relative levels of
35S-proinsulin monomers in (B) or (D) of individual immunoprecipitates (on the reduced gel) were shown in (A) and (C), respectively. The data in (A) or
(C) were reported as mean 6 SD. n=3. *P,0.05; **P,0.01. % cont (Pro): percentage of proinsulin monomer level compared to the control.
doi:10.1371/journal.pone.0027647.g001
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+/+ b-cells,
exposure to Chx (Figures 2, 3, 4), generally enhanced b-tubulin,
an internal marker. In the sympathetic neurons, tubulin half-life
increased when Chx inhibited protein synthesis [25]. b-tubulin
fluctuation in Ins2
+/+ b-cells may also be affected by the change in
turnover, irrespective of other possibilities, such as an increased
proportion of b-tubulin in the whole-cell protein pool as a
consequence of imbalanced input and output of abundant
secretory protein. Thus, non-normalized accumulations of proin-
sulin in the addition of Chx and lysosomal or proteasomal
inhibitors are generally more severe (Figures 2, 3, 4, 5).
Roles of lysosomes and proteasomes at sequential stages
of the proinsulin post-translational process
Nascent proinsulin normally exits from the ER after 20 minutes
[18,20], moves sequentially into the Golgi and trans-Golgi
network, and reaches into the immature insulin granule in about
45 to 60 minutes, and then completes conversion to insulin within
the mature granule for release in approximately 2 hours [18]. To
determine the roles of lysosomes and proteasomes in the sequential
stages, we added selective inhibitors at 0, 30, and 60 minutes in a
2-hour post-translational course with Chx. Compared to the
untreated control, 14% of proinsulin molecules were retained in
the 2-hour treatment with Chx, 24% with combined Chx/
lactocystin/MG-132, and 41% with combined Chx/chloroquine/
E-64 (see % below image iv in Figure 3 and details in Table S2).
Addition of the combined lysosomal inhibitors thus preserved 27%
of proinsulin and addition of the proteasomal inhibitors, 10%, in
the 2-hour course (P,0.05, n =4), an effect resembling that of
applying individual inhibitors (Figure 2). Addition from 30 to 120
minutes of chloroquine/E-64 led to the preservation of 18% of
proninsulin (P,0.05, n =4) and addition of lactacystin/MG-132,
to a slight (5%) preservation. However, adding either combined
inhibitor from 60 to 120 minutes produced no apparent
accumulation of proinsulin.
Thus, examination of proinsulin monomers under reduced
conditions reveals that proteasomal inhibition within the first 30
minutes of the post-translational 2-hour course indeed preserves 5
to 10% of proinsulin in the islets and cloned b-cells (Figures 1, 2,
3). This slight increase is barely noticeable in the various states of
proinsulin shown under non-reduced conditions (Figure 3, images
i and ii), but under reduced conditions, the density of the
proinsulin monomers and of several bands resistant to dithiothre-
itol (DTT) and 2-mercaptoethanol and having high molecular
weights increased by addition of combined lactocystin/MG-132 or
chloroquine/E-64 from 0 to 120 minutes (Figure S2). At least
some of these bands, expected to be components of proinsulin
states [1], may represent proinsulin modified with non-disulfide
covalent bonds by other molecules, such as ubiquitin, because the
pattern of proinsulin non-monomer states somewhat resembles
that of b-cell protein ubiquitination (Figure 3, image i or ii versus
right panel). Therefore, the denoted A to F band/area of
proinsulin non-monomer states under non-reduced condition [1]
could include aggregates shaped by proinsulin alone and/or with
molecular helpers through (non-)covalent interactions. Some
aggregates on non-reduced gels or membranes could contain
closely migrated DTT-resistant and -sensitive forms.
In untreated cells, the pattern of proinsulin states (Figure 3,
images i and ii) is compatible with the pattern observed previously
[1]. In all the treatments (with Chx alone or combined with
inhibitors), proinsulin monomers (denoted as a and b) disappeared
similarly except when chloroquine with E-64 was added from 0 or
30 minutes to 120 minutes. Monomer b, but not a, was retained
selectively in the 2 excluded treatments; regardless of other
Figure 2. Validation of proteasomal or lysosomal roles in the disposal of proinsulin. After 24-hour pre-experimental culture with the
5.5 mM glucose concentration, the Ins2
+/+ b-cells were exposed to cycloheximide (Chx; 100 mg/mL); Chx and chloroquine (50–400 mg/mL); Chx and E-
64 (25–100 mM); Chx and lactacystin (5–20 mM); or Chx and MG-132 (10–120 mM) for 2 hours with an untreated control. Cellular proteins (30 mg) were
separated on16.5% tricine SDS-PAGE under reduced conditions and then examined by C-peptide or b-tubulin antibody on the same membrane. %
cont (Pro): percentage of the (average) proinsulin level in individual treatments compared to the untreated control. % cont (Pro/T): percentage of the
(average) proinsulin level in individual treatments compared to the untreated control and normalized by b-tubulin. The data were shown as mean.
Statistical significances (*P,0.05; **P,0.01) of the normalized proinsulin level between Chx and individual treatments that included Chx were
assessed by two-tailed t-test (n=4).
doi:10.1371/journal.pone.0027647.g002
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form b, a possible isomer [1]. These observations suggest that the
consequent transport and processing (see insulin data below) of the
natively folded proinsulin was not markedly altered during the
diverse durations of lysosomal or proteasomal inhibition in the
limited 2 hours. If prolonged, severe accumulation of non-
monomer states and form b from lysosomal inhibition from 0 or
30 to 120 minutes could result in consequences, such as insulin
production and other biological abnormalities in b-cells.
Immunoblot analysis showed a decrease in normalized insulin
level (under non-reduced conditions) in all treatments that
included Chx (see image iii in Figure 3 and details in Table S3),
which enhanced b-tubulin, as discussed (Figure 2). Insulin levels
were roughly similar among the treatments combining Chx with
inhibitors. However, a noticeable decrease in insulin in the
presence of chloroquine/E-64 from 60 to 120 minutes (Table S3,
p,0.05, n =4) may be linked to the condensation of insulin and
stability of the cores in immature granules [20,26]. It is well known
that the insulin secreted in a few hours under low (e.g., 5.5 mM)
glucose conditions is only a tiny fraction of the entire cellular
insulin content. Thus, except for the excluded treatment, diverse
times of lysosomal and proteasomal inhibition during the 2 hours
apparently had no obvious effect on insulin content, irrespective of
the undetermined secreted insulin. These data further support that
the accumulated proinsulin is mainly destined for natural
clearance rather than for the customary route in insulin
biosynthesis. Interestingly, the immunoreactivity of separated
insulin A and/or B chains detected under reduced conditions
was noticeably low in the b-cells exposed to chloroquine/E-64 or
lactocystin/MG-132 for 2 hours (data not shown), but the reasons
are unclear. Nonetheless, in the early post-translational process of
proinsulin, a prolonged or permanent alteration or defect caused
by any reason(s) appears to have profound toxic consequences on
insulin biosynthesis and even b-cell survival; diabetes resulting
from proinsulin mutants provides genetic evidence [2–4]. In
addition, compared to the untreated control, the slightly improved
proinsulin conversion to insulin when protein synthesis is inhibited
in the treatment of Chx only suggests that a consistent overload
may exist for folding in the ER of pancreatic b-cells, which may
partially result from the low relative folding rate versus plentiful
amounts of insulin precursor made in b-cells [1].
Collectively, these results clearly indicate that the main
lysosomal pathway and auxiliary proteasomal pathway function
together during the early post-translational process of proinsulin,
during which regulations in the ER translocation [15], structural
maturation, and (retro-) translocation/transport take place.
Endogenous proinsulin removal is a substrate-favored
process
To determine whether proinsulin is selectively removed among
secretory proteins, we conducted immunoblot analysis of the
kinetics of insulin and islet amyloid polypeptide (IAPP) precursors
in a 30-minute post-translational process. Compared to the
untreated control, about 67% of proinsulin molecules were
retained with Chx treatment, 85% with Chx/lactacystin/MG-
132, and 115% with Chx/chloroquine/E-64; the apparently
Figure 3. Lysosomal and proteasomal roles at sequential stages of the proinsulin post-translational process. The Ins2
+/+ b-cells were
cultured under the 5.5 mM glucose concentration for a 24-hour pre-experimental period until treatment. Cycloheximide (Chx; 100 mg/mL); or Chx
(100 mg/mL), chloroquine (100 mg/mL), and E-64 (50 mM); or Chx (100 mg/mL), lactacystin (10 mM), and MG-132 (30 mM) was added to the culture
media of Ins2
+/+ b-cells at 0, 30, or 60 minutes during a 2-hour course with an untreated control. Cellular proteins (30 mg) were separated on16.5%
tricine SDS-PAGE under non-reduced/reduced conditions and then examined by immunoblotting. C-peptide (images I and ii, non-reduced condition;
image iv, reduced condition); insulin (image iii, non-reduced condition); b-tubulin (image iii, non-reduced condition; image iv, reduced condition); or
ubiquitin (right panel, reduced condition; untreated control shown). Images i (shorter exposure), ii (longer exposure), and iii were produced from the
same membrane. C-peptide or tubulin immunoblot data shown in image iv were produced from the same membrane. The levels of insulin (Ins) or
proinsulin (Pro) compared to the untreated control (% cont [Ins; Pro], non-normalized; % cont [Ins/T; Pro/T], normalized by b-tubulin) are shown at
the bottom, below images iii and iv. Ub, ubiquitin; IB, immunoblot. The proinsulin states were denoted previously (1). Statistical significances of the
normalized proinsulin level between Chx and other treatments including Chx, or of the normalized insulin level between the chloroquine/E-64
presence from 60 to 120 minutes versus other treatments combining proteasomal/lasosomal inhibitors with Chx were assessed. The data were shown
as mean. *, P,0.05; **, P,0.01; n=4. The statistical results were detailed in Table S2 and S3.
doi:10.1371/journal.pone.0027647.g003
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insulin biosynthesis was apparently unaltered in the limited 30
minutes (Figure 4A and Table S4). Thus, approximately 18% of
the proinsulin targeted mainly for natural disposal was preserved
by 30-minute proteasomal inhibition and 48%, by lysosomal
inhibition (Chx versus Chx/lactacystin/MG-132, P,0.05; Chx
versus Chx/chloroquine/E-64, P,0.01; n=4). The patterns of
IAPP and its precursors agreed with those of previous studies
[27,28] in untreated Ins2
+/+ b-cells. By contrast, only 3, 3, and 7%
of islet amyloid polypeptide precursor (proIAPP) molecules were
retained sequentially in the 3 treatments (Table S4 and bottom
panel in Figure 4A). Similar to findings in insulin, no significant
alteration in IAPP content in all treatments was evident during the
30 minutes chase notwithstanding a slight decline with the
chloroquine/E-64 treatment. Theoretically, proIAPP should also
undergo ER quality control after removal of signal peptide from
preproIAPP by a co/post-translational translocation process (see
review: 29) observed in early studies of preproinsulin [30–33].
However, lysosomal or proteasomal inhibition did not cause
noticeable accumulation of proIAPP in the same course, and
although the half-time of proIAPP conversion into IAPP is faster
than the half-time of proinsulin conversion into insulin, it still
requires about 25 minutes [28]. Obviously, addition of Chx
reduces this time considerably, demonstrates by the barely
detectable proIAPP in all treatments that include Chx despite
the presence of a large amount of proIAPP in the untreated
control (Figure 4A). Clearly, the post-translational process of IAPP
precursors is enhanced, and the enhancement is barely affected by
lysosomal or proteasomal inhibition during the 30 minutes.
Antimycin largely inhibits the heavy clearance of
35S-proinsulin
in MIN6 b-cells (Figure 1) [1]. In Ins2
+/+ b-cells exposed to
antimycin for 5 minutes, the level of immunoreactive proinsulin
increased to 180%, of prohormone convertase 2 (PC2) precursor
to 127%, and of PC2, a functional convertase in insulin
biosynthesis, to 103% (Figure 4B and Table S5; P,0.01;
P,0.05; non-significant, n=4). Antimycin significantly inhibited
protein synthesis [34], further supporting that the preferential
accumulation of proinsulin results mainly from attenuation of a
substrate-favored clearance. After a subsequent 30-minute chase,
approximately 168% of proinsulin remained in the b-cells
(P,0.01, n=4). In contrast, the slightly accumulated proPC2
disappeared as the PC2 correspondingly increased in the same
course (Figure 4B and Table S5). The autoactivation of ProPC2
into PC2 occurs at the trans-Golgi network [18], suggesting that
Figure 4. Endogenous proinsulin removal is a substrate-favored process. The Ins2
+/+ b-cells were cultured under the 5.5 mM glucose
concentration for a 24-hour pre-experimental period until treatment. (A) The Ins2
+/+ b-cells were treated with cycloheximide (Chx; 100 mg/mL), Chx
(100 mg/mL), lactacystin (10 mM), and MG-132 (30 mM), or Chx (100 mg/mL), chloroquine (100 mg/mL), and E-64 (50 mM) for 30 minutes with an
untreated control. Cellular proteins (30 mg) were separated by 16.5% non-reduced/reduced tricine SDS-PAGE and then examined by immunoblotting.
The C-peptide or islet amyloid polypeptide (IAPP) immunoblot data under reduced condition in (A) were produced from the same membrane. The
percentages of proinsulin (Pro), insulin, or ProIAPP peptide levels in individual treatments compared to the untreated controls are shown at the
bottom, below the images in (A). Statistical significances (*P,0.05; **P,0.01) of the proinsulin or proIAPP level between Chx and individual
treatments that included Chx were assessed (n=4). The statistical results were detailed in Table S4. (B) The Ins2
+/+ b-cells in 2 dishes were treated with
10 mM of antimycin for 5 minutes with 2 untreated dishes, and then half of the untreated and treated dishes were chased for 30 minutes and the
other half harvested immediately. Cellular proteins (30 mg) were separated by 16.5% reduced tricine SDS-PAGE and then examined by C-peptide or
PC2 antisera on the same membrane. The percentages of proinsulin (Pro), ProPC2, or PC2 peptide levels in individual treatments compared to the
untreated controls are shown at the bottom, below the images in (B). The data were shown as mean. Statistical significances (*P,0.05; **P,0.01) of
the proinsulin, proPC2, or PC2 level between the indicated groups were assessed (n=4). The statistical results were detailed in Table S5.
doi:10.1371/journal.pone.0027647.g004
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the 30-minute chase. Likewise, prohormone convertase 1/3 (PC1/
3), another convertase autoactivated in the ER [18], does not
undertake noticeable clearance when proinsulin is heavily
removed [1]. Thus, endogenous proinsulin is selectively and
largely removed by energy-sensitive clearance processes during the
maturation and transport of secretory proteins.
A role of macroautophagy in the removal of endogenous
proinsulin
To establish whether the role of lysosomes in proinsulin disposal
is mainly achieved through macroautophagy and/or other
mechanisms like CMA, we next examined the effect of autophagy
inhibitors 3-methyladenine (3-MA) and bafilomycin A1 (Baf A1)
versus chloroquine on kinetics of proinsulin. Compared to
chloroquine that targets the entire lysosomal lumen, 3-MA inhibits
macroautophagy by blocking autophagosome formation and Baf
A1 prevents maturation of autophagic vacuoles by inhibiting
fusion between autophagosomes and lysosomes and inhibiting
lysosomal acidification [35,36]. In a 30 minutes post-translational
course by presence of Chx in Ins2
+/+ b-cells, addition of 3-MA
(5 mM), Baf A1 (5 mM), or chloroquine (100 mg/mL) resulted in
changes in the ratio of microtubule-associated protein 1 LC3-I/II,
an internal marker showing activities of the autophagic process.
LC3-I is a cytoplasmic form. In contrast, LC3-II, a product
converted from LC3-I, is an autophagic membrane binding form
and its amount correlates well with the number of autophago-
somes [37]. The occurrence of the increased LC3-II and LC3-I/II
Figure 5. Macroautophagy is a major mechanism in the rapid disposal of insulin precursor in b-cells. The Ins2
+/+ b-cells were cultured
under the 5.5 mM glucose concentration for a 24-hour pre-experimental period until treatment. (A) The Ins2
+/+ b-cells were treated with
cycloheximide (Chx; 100 mg/mL), Chx (100 mg/mL) and 3-MA (5 mM), Baf A1 (5 mM), or chloroquine (Chl; 100 mg/mL) for 30 minutes with an untreated
control. Cellular proteins (30 mg) were separated by 16.5% non-reduced (upper panels) or reduced (lower panels) tricine SDS-PAGE and then
examined by immunoblotting. (B) The upper panel, the immunoreactive LC3-I/II (%) in individual treatments in (A); the lower panel, the percentages
of proinsulin levels on reduced gels (that were normalized by tubulin) in individual treatments compared to the untreated controls. (C) The Ins2
+/+ b-
cells subjected to the same treatments described in (A) were immunostained with antibodies against LC3, C-peptide, and insulin as described in the
Materials and Methods. Fluorescent Cy2 (for LC3), Cy3 (for C-peptide and insulin), and their merged images were shown. The scale of bar in (C),
10 mm. (D) The relative levels (%) of the LC3 and (pro)insulin and/or C-peptide positive dots per cell of individual treatments in (C). The data in (B) or
(D) were reported as mean 6 SD. *P,0.05; **P,0.01, n=4.
doi:10.1371/journal.pone.0027647.g005
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conversion to LC3-II by 3-MA (Figure 5A and B) is in an
agreement with previous observations in pancreatic b-cells and
other cell types [37,38]. Optimal concentrations of Baf A1 in our
acute post-translational studies (data not shown) were higher than
the concentrations used in the studies reported previously [36,38].
These results indicate the autophagic process blocked by these
agents.
In the same post-translational processing course, approximately
20, 29, and 37% of the proinsulin targeted mainly for disposal was
preserved by the presence of 3-MA, Baf A1, or chloroqunine,
respectively (Figure 5A and B;P ,0.05; P,0.01; P,0.01; n=4),
The results indicate these inhibitors that affect sites diversely in the
macroautophagic process or lysosomal compartments preserve
different amounts of proinsulin, and suggests macroautophagy is
an important mechanism for rapid proinsulin disposal. In
consistent with this observation, immunohistochemistry examina-
tions exposed a similar tendency in the increase of LC3 and
(pro)insulin and/or C-peptide co-localized dots induced by these
three agents compared to the control treatment with Chx only in a
30 minutes post-translational course (Figure 5C and D;P ,0.05;
P,0.01; P,0.01; n=4). These results clearly show that macro-
autophagy is an important but not the sole mechanism for the role
of lysosomes in the insulin precursor disposal of b-cells. This is
because the amount of proinsulin preserved by 3-MA (that blocks
autophagosome formation) is less than that by Baf A1, which
prevents fusion between autophagosomes and lysosomes and affect
acidification of lysosome via the inhibition of vacuolar-type H
+-
ATPase. Moreover, the most plentiful amount of proinsulin is
preserved by chloroquine, which is a powerful inhibitor of
lysosomal acidification via preferential accumulations in the
lysosomal lumen of cells [21,22].
Discussion
Roles of the lysosomal and proteasomal pathways in the
early post-translational processing of insulin precursor
Over 30% of
35S-Met-labeled nascent proinsulin in islets or 30
to 60% in MIN6 b-cells is rapidly removed within a 20-minute
chase (Figure 1), a finding consistent with previous observations
[1]. Immunoblotting analysis further validated that at least 30% of
total proinsulin in Ins2
+/+ b-cells is cleaned, mainly during a 60-
minute post-translational process (Figures 2, 3, 4). Thus, a large
fraction of proinsulin is unquestionably removed during the
natural process of maturation and transport despite the degree of
removal seems to be somewhat different between primary and
cloned b-cells. In this study with selective inhibitors, we define the
lysosomal and proteasomal pathways as involved in the proinsulin
removal. Both metabolic-labeling and immunoblotting studies
suggest that lysosomal autophagy is primarily responsible for the
rapid proinsulin disposal following translation (Figures 1, 2, 3, 4),
and both pathways carry out the subsequent basal clearance,
which possibly occurs after translocation into the ER. Thus,
multiple mechanisms at the molecular level yet to be defined
participate in PIHO at the early secretory pathway. These findings
also provide a better understanding of the cellular mechanisms
underlying (a) the occurred b-cell dysfunction and diabetes in the
mice with deletion of Atg7 (which is an essential molecule in the
formation of autophagosomes) [39,40] and (b) a showed link of the
proteasomal pathway and insulin secretion [41–43]. The proin-
sulin non-monomer states and their dual fates that were recently
exposed [1] are consistently observed in this study (Figures 1, 2, 3,
4). The data further enforce the in vivo formation nature of these
non-monomer states [1]. Molecular helpers located in the non-
monomer states, which may facilitate regulations of proinsulin
maturation and disposal [1], remain to be identified.
Of note, applications of (a) C-peptide antisera, (b) C-peptide
immunoblotting and metabolic-labeling approaches for analysis of
proinsulin states/levels, and (c) selective inhibitors are important in
disclosing the roles of lysosomal and proteasomal pathways in
normal proinsulin PHIC. As shown, proinsulin non-monomers
(and even monomer b) showed lower affinity with the high
conformation-dependent insulin antisera [44] than with C-peptide
antisera (see proinsulin states on a membrane detected by insulin
or C-peptide antisera, Figures 3, images i-iii, and S3). The finding
from these immunoblot results is consistent with that found
recently in immunoprecipitation studies [1]. These data further
suggest application of C-peptide antisera is helpful for adequate
detection of incompletely folded proinsulin non-monomers,
although the insulin antisera are employed as master antibodies
in the early and current study of proinsulin folding and related b-
cell biology.
On the other hand, traditional pulse-chase approached showed
that without C-peptide immunoblotting, proinsulin state analysis,
and application of selective inhibitors, the states and rapid disposal
of proinsulin cannot adequately be determined. Moreover, only
studies with electron microscope disclosed lysosomal degradation
of proinsulin, and those with some difficulty, because previous
studies within the crinophagic body, a compartment fused with the
lysosome for turnover of insulin granules, barely detected C-
peptide immunoreactivities [45]. A possible explanation is that
soluble C-peptide degrades more easily/rapidly than the relatively
insoluble insulin crystals in the crinophagic body [45].
Preferential disposal of insulin precursor in the
maturation and transport process of secretory proteins in
b-cells
Our immunoblot analysis of insulin, IAPP, and PC2 proteins
and their precursors clearly indicates the preferential disposal of
endogenous proinsulin among secretory proteins during their
maturation and transport processes in b-cells (Figure 4). This
observation is in agreement with the previous finding in metabolic-
labeling studies that a large fraction of nascent proinsulin is
selectively removed by comparison with other secretory proteins
such as IAPP, PC1/3, and their precursors [1]. Such a selective
disposal may be linked to the intrinsic properties of proinsulin in
vivo, such as its low relative folding rate and proneness to
aggregation [1]. These properties could depend mainly on the
topology of (pre)proinsulin determined by the primary amino acid
sequence [46]. In addition, the mechanisms of substrate-specific
translocation/ERAD for some proteins (see reviews: 5, 6) may be
similarly implicated in the favored disposal of endogenous
proinsulin.
Mechanisms for the removal of endogenous proinsulin in
b-cells
The results (Figures 1, 2, 3, 4) in this study at the first time
suggest that multiple disposal mechanisms participate in proinsulin
disposal for the normal maintenance of PIHO at the early
secretory pathway. Further analysis with (non)selective macro-
autophogy inhibitors and marker clearly defined that macro-
autophagy is an important mechanism involved (Figure 5). In
addition to the defined role of macroautophagy in the bulky and
rapid removal of proinsulin, CMA may be a likely participating
mechanism considering the substrate-favored natures of insulin
precursor disposal. Likewise, the occurrence of proinsulin disposal
extends beyond a 30 minutes post-translational course (Figure 3),
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may be also active for proinsulin disposal during the natural
maturation and transport processing for insulin production. This is
in agreement with the observations in early insulin biosynthesis
studies [18]. Moreover, our data (Figures 1, 2, 3, 4) suggest that the
ERAD proteasomal pathway also plays a role in counterbalancing
the natural proinsulin maturation and transport processing under
physiological glucose concentrations.
The sustained active rapid and favored clearance route of
insulin precursor may serve a protective or adaptive mechanism
for maintenance of the ER function in addition to its participating
in the early control of insulin production. This route can early
eliminate excessive or misfolded insulin precursor when overloads
occur by stimuli (such as high glucose) or proinsulin folding
processing is disturbed by various influences. Nonetheless, a
prolonged or permanent alteration/defect in the disposal and/or
counterbalanced maturation routes could result in profound toxic
consequences on insulin biosynthesis and whole function of b-cells.
For example, heterogeneous mutations at the residues beyond the
cleavage sites in the preproinsulin molecule produce hyper- and
hypo(pro)insulinemia, contrasting syndromes in mouse and/or
humans [2–4,18]. The contrasting syndromes would be a result of
atypical maturation and disposal process integrations primarily/
largely induced by varied mutants.
In summary, our improved metabolic-labeling and C-peptide
immunoblotting approaches revealed the favored and bulky
removal of insulin precursor at the early stage of normal insulin
biosynthesis under the conditions with mimic physiological glucose
concentrations. This study determined the roles of lysosomal and
proteasomal pathways in the normal maintenance of PIHO, and
defined the physiological participation of lysosomal autophagy in
the regular quality control of secretory proteins. The findings will
help elucidate the actual pathological defects and mechanisms in
diabetes with PIHO disorders. Whether the ubiquitin-proteasome
and autophagy-lysosome systems are cross-talked or independent
in (a) typical proinsulin disposals and what the real underlying
molecular mechanisms are deserve further study. Knowing the
answers to these questions might ultimately lead to novel means to
preserve or restore insulin production capacity in prevention and
treatment of diabetes.
Materials and Methods
Ethics statement
All animal and tissue sample experiments have been approved by
the Institutional Animal Care and Use Committee (IACUC) of The
Ohio State University (protocol number 2007A0040 and
2010A0024) and were performed in accordance with the guidelines
of the National Institutes of Health and The Ohio State University.
Materials
In this study, we applied antibodies against mouse C-peptide II
(made in the lab with help from Proteintech Group, Inc., Chicago,
IL, USA), rat C-peptide II (Linco Research Inc., St. Louis, MO,
USA), insulin (Dako North America, Inc., Carpinteria, CA, USA),
and tubulin (Sigma-Aldrich, St. Louis, Mi, USA), ubiqutin (Sc-
8017; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), LC3
(NB100-2331; Novus Biologicals Inc., Littleton, CO), PC2 (kindly
provided by Dr. Donald F. Steiner, Chicago), and IAPP antibodies
(kindly provided by Dr. P. Westermark, Linko ¨ping, Sweden). We
obtained N-ethylmaleimide (NEM), Chx, antimycin, brefeldin A,
bafilomycin A1, chloroquine, 3-methyladenine, E-64, and MG-132
from Sigma; lactacystin from Cayman Chemical Company, Ann
Arbor, MI, USA; Met-free Dulbecco’s modified eagle’s medium
(DMEM) and Roswell Park Memorial Institute (RPMI) 1640 from
Invitrogen (Carlsbad, CA, USA); and protease inhibitor cocktail
from Roche Applied Science (Indianapolis, IN, USA). We obtained
Immobilon-P
SQ membrane from Millipore (Bedford, MA, USA);
[
35S]-Met from Perkin Elmer (Waltham, MA, USA), and C57BL/
6Jmice fromTheJacksonLaboratory(BarHarbor,ME,USA).The
clonedIns2
+/+b-cellswere kindlyprovidedbyDr.H.Kubota (inthe
laboratory of Dr. K. Nagata, Kyoto, Japan), and MIN6 b-cells were
a gift from Dr. Donald F. Steiner (Chicago, IL, USA).
Islet preparation and cell culture
In this study, all operations and materials used were kept away
from reducing reagents unless specifically stated. Islet isolation and
culture of islets and cell lines were described previously [2,24].
Briefly, we incubated the cells in 35-mm dishes in DMEM
(25.5 mM glucose) supplemented with 10% fetal bovine serum plus
(FBS) at 37uC with 5% CO2/95% O2 until 80–90% confluence for
24-hour pre-experimental and various experimental treatments
with 5.5 mM glucose. We cultured isolated islets overnight in 10%
FBS/RPMI 1640 (11 mM glucose) until treatment.
Pulse and/or chase
After 30 minutes of preincubation in Met-free DMEM (for
MIN6 b-cells) or Met-free RPMI 1640 medium (for islets), mouse
islets or MIN6 b-cells were labeled with
35S-Met in the same
media. We utilized pre-balanced complete DMEM/10% FBS
(5.5 mM glucose) or RPMI 1640/10% FBS (11 mM glucose)
media with and without various inhibitors in the various chase
tests. After pulse and/or chase incubations, islets and MIN6 b-cells
were quickly washed with PBS containing 20-mM NEM and
immediately lysed in the immunoprecipitation buffer and frozen at
280uC. After the various post-translational courses (Figures 2, 3,
4, 5), the Ins2
+/+ b-cells were quickly washed and immediately
lysed in the tricine gel sample and frozen at 280uC.
Protein extraction buffers and sample preparations
We extracted cellular proteins by the tricine gel sample buffer
(100 mM Tris, pH 6.8, 1% sodium dodecyl sulfate [SDS], 20%
glycerol, 20-mM N-ethylmaleimide, and 0.02% Coomassie Blue)
for immunoblotting and by immunoprecipitation buffer (50 mM
Tris.HCl, pH 7.4, 100 mM NaCl, 2.5 mg/mL BSA, 1% Triton
X-100, 20 mM NEM, and protease inhibitor cocktail) for
immunoprecipitation analysis.
Lysed cells were then subjected to sample preparations
described previously [1].
SDS-PAGE, immunoblotting, immunoprecipitation, and
radioautography
We boiled proteins for 10 minutes in tricine gel sample buffer
with and without 280 mM 2-mercaptoethanol for separation on
the tricine SDS-PAGE without urea (10% T and 5% C, Figure 1B,
C; 16.5% T and 5% C, Figures 2, 3, 4, 5; T denotes the total
percentage concentration of both acrylamide and bisacylamide; C
denotes the percentage concentration of the bisacylamide relative
to the total concentration). Immunoblotting and immunoprecip-
itation were performed following procedures described previously
[1]. For autoradiography, we dried membrane and fixed gels with
labeled materials for exposure on x-films.
Immunohistochemistry
Ins2
+/+ b-cells seeded on cover-glass were cultured in the
customary 10% FCS/DMEM medium for 48 h and then
subjected to 24-hour pre-experimental and 30 minutes experi-
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+/+
b-cells were fixed with pre-cold methanol for 5 minutes and then
immunostained with antibodies against LC3 (1:150), C-peptide
(1:200), and insulin (1:500) as described previously [2]. Fluorescent
images of Cy2 for LC3 and Cy3 for C-peptide and insulin were
examined with an Axiovert 200 microscope (Carl Zeiss, Oberko-
chen, Germany). To quantify the LC3 and (pro)insulin and/or C-
peptide co-localized dots per cell, the number/area of the co-
localized dots in 15 cells of individual treatments were counted
from four independent experiments.
Quantitative analysis of immunoreactivity and
radioactivity
To quantify the density and radioactivity of proteins (area and/
or gel slices), we used National Institutes of Health (NIH) ImageJ
software and/or liquid scintillation counter and gamma counter
(Beckman Coulter, Inc., Brea, CA, USA).
Data Analysis
Data are presented as the mean or mean 6 standard deviation
(SD, n=3 or 4). We assessed statistical significance (*P,0.05;
**P,0.01) by two-tailed Student’s t-test.
Supporting Information
Figure S1 No proinsulin was detected in the immuno-
precipitates of control sera. After 24-hour pre-experimental
culture with the 5.5 mM glucose concentration, MIN6 b-cells were
chased for 3 minutes after a 5 minutes pulse with
35S-Met. Cellular
proteins were then subjected to immunoprecipitation with insulin
(Ins) and C-peptide (Cp) antisera or with control sera (C). Equal
amounts of individual immunoprecipitates were resolved by 10%
tricine non-reduced and/or reduced SDS-PAGE for radiography.
(TIF)
Figure S2 A longer exposure image of cellular proinsu-
lin in the C-peptide immunoblot analysis after resolu-
tion under reduced condition. Figure 3, image iv has a
shorter exposure. This longer exposure image showed that the
density of several dithiothreitol (DTT)-resistant bands of high
molecular weight increased by addition of Chx, lactocystin, and
MG-132 or Chx, chloroquine, and E-64 from 0 to 120 minutes
compared to the addition of Chx alone in the same course.
(TIF)
Figure S3 A longer exposure image of cellular (pro)in-
sulin in the insulin immunoblot analysis after resolution
under non-reduced condition. On the same membrane, the
various proinsulin non-monomer states that were clearly detected
by C-peptide antisera (see Figure 3, images i and ii) were weakly
detected by conformation-dependent insulin antisera at shorter
(Figure 3, image iii) and longer (this image) exposure conditions.
(TIF)
Table S1 Relative levels of labeled proinsulin mono-
mers in the individual treatments shown on the reduced
gel in Figure 1B.
(PDF)
Table S2 Relative levels of proinsulin monomers in the
individual treatments shown in the image IV of Figure 3.
(PDF)
Table S3 Relative levels of insulin monomers in the
individual treatments shown in the image III of Figure 3.
(PDF)
Table S4 Relative levels of proinsulin or ProIAPP mono-
mers in the individual treatments shown on the reduce
gel in Figure 4A.
(PDF)
Table S5 Relative levels of proinsulin, ProPC2, or PC2
proteins in the individual treatments shown on the
reduce gel in Figure 4B.
(PDF)
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